Findings

What do systematic reviews say?

166 questions · 177 findings · 9 reviews · Metabolic and Endocrine Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 86 · 48.6%GRADE not reported 8 · 4.5%Very low 44 · 24.9%Low 38 · 21.5%Moderate 1 · 0.6%High 0 · 0%

Metformin vs dipeptidyl‐peptidase 4 inhibitors

Non‐fatal stroke

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 543 participants
Very low

Metformin vs dipeptidyl‐peptidase 4 inhibitors

End‐stage renal disease

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs glucagon like peptide‐1 analogues

All‐cause mortality

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 807 participants
Very low

Metformin vs insulin

Quality of life Short‐Form 36 health survey (SF‐36)

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 91 participants
Very low

Metformin vs glucagon like peptide‐1 analogues

SAEs

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 807 participants
Very low

Metformin vs glucagon like peptide‐1 analogues

Health‐related quality of life

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs glucagon like peptide‐1 analogues

Cardiovascular mortality

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 807 participants
Very low

Metformin vs glucagon like peptide‐1 analogues

Non‐fatal MI

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 807 participants
Very low

Metformin vs glucagon like peptide‐1 analogues

Non‐fatal stroke

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 807 participants
Very low

Metformin vs glucagon like peptide‐1 analogues

End‐stage renal disease

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs meglitinides

All‐cause mortality

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs meglitinides

Serious adverse events

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 112 participants
GRADE not reported

Metformin vs meglitinides

Health‐related quality of life

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs meglitinides

Cardiovascular mortality

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs insulin

Cardiovascular mortality

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs meglitinides

Non‐fatal MI

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs meglitinides

Non‐fatal stroke

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs meglitinides

End‐stage renal disease

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs insulin

Non‐fatal MI

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs insulin

Non‐fatal stroke

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found